Hayashi, Naomi
Mori, Seiichi
Ohmoto, Akihiro
Fukada, Ippei
Yamazaki, Masumi
Hosonaga, Mari
Wang, Xiaofei
Ueki, Arisa
Kiyotani, Kazuma
Tonooka, Akiko
Takeuchi, Kengo
Takahashi, Shunji
Article History
Received: 11 July 2023
Accepted: 6 April 2024
First Online: 26 April 2024
Declarations
:
: None of the authors have a conflict of interest to report for the submitted work. AU has received research support from Pfizer outside the submitting work. KK reports employment from Cancer Precision Medicine,Inc. KT has received consultancy fees from Nichirei Bioscience, Nippon Shinyaku, and Meiji Seika Pharma; research support from Fujirebio and Daiichi Sankyo; honoraria from Eli Lilly, Chugai, Kyowa Kirin, and Janssen; and royalties from Sysmex and Nichirei bioscience outside the submitting work. ST has received research support from ONO Pharmaceutical Co., Ltd., Bristol-Myers Squibb, MSD, AstraZeneca, Chugai, and BAYER; and honoraria from Chugai outside the submitting work.
: All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This observational study was approved by the institutional review board of the Japanese Foundation for Cancer Research (approval number 2021-GA-1075). Patient consent for this study was obtained in the form of an opt-out form.